Learn about the ROS1 treatment landscape and managing treatment side effects with thoracic oncologist Dr. Estelamari Rodriguez.

This episode is sponsored by Nuvation Bio.

In Part 2 of the Young Lung Cancer Initiative ROS1 Biomarker Series, we dive into the "meat and potatoes" of treatment with Dr. Estelamari Rodriguez, a thoracic oncologist at Sylvester Comprehensive Cancer Center at the University of Miami.

This educational video explores the current standard of care for ROS1 positive lung cancer, from early-stage management to metastatic disease. Dr. Rodriguez discusses the evolution of targeted therapies—including next-generation tyrosine kinase inhibitors (TKIs) and explains how these newer drugs are moving the needle for patients with brain metastases.

The conversation provides practical suggestions on navigating common ROS1 TKI side effects, such as dizziness (CNS effects), taste changes, and GI issues. Dr. Rodriguez emphasizes why open communication with your care team about dose adjustments and "drug holds" is vital for maintaining a high quality of life while staying on treatment longer.

Coming Up Next: In Part 3, we will conclude the series by discussing the reality of "Living with ROS1," including progression, long-term survivorship, and the future of research.

Learn the fundamentals of ROS1 positive lung cancer, biomarker testing, and brain metastasis with thoracic oncologist Dr. Estelamari Rodriguez.

This episode is sponsored by Nuvation Bio.

In Part 1 of the Young Lung Cancer Initiative ROS1 Biomarker Series, we introduce the fundamentals of ROS1 positive lung cancer with Dr. Estelamari Rodriguez, a thoracic oncologist at Sylvester Comprehensive Cancer Center at the University of Miami.

This educational video explains what the ROS1 biomarker is, how ROS1 gene fusions occur, and how often ROS1 is found in non small cell lung cancer (NSCLC). Dr. Rodriguez discusses why comprehensive biomarker testing, including molecular and genomic testing at diagnosis, is essential for identifying ROS1 positive lung cancer and guiding treatment decisions.

The conversation also addresses central nervous system (CNS) involvement, including how often brain metastases are present at diagnosis in ROS1 positive lung cancer, and why brain imaging is an important part of initial staging and evaluation.

This episode is designed for patients, caregivers, and advocates seeking patient friendly cancer education about lung cancer biomarkers. It serves as the foundation for the ROS1 Biomarker Series. Future episodes will cover ROS1 targeted therapy, tyrosine kinase inhibitors (TKIs), treatment side effects, and emerging research for people living with ROS1 positive lung cancer.